Latest Share Chat

REMOVE ADS

Avacta Group Share News (AVCT)

Avacta Group Information

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

71.00 1.00 (1.43%)

Bid:

70.00

Ask:

72.00

Spread: 2.00 (2.857%)

Market Cap: £323.13m

Last checked at -

Intraday Avacta Group Share Chart

REMOVE ADS

Avacta Group News

Avacta 'delighted' at license agreement with longtime collaborator

(Sharecast News) - Avacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise a science and research assay project using...

Avacta hails progress on in-house and third-party programmes

(Sharecast News) - Avacta Group posted a slightly wider full-year loss on Wednesday even as it highlighted progress both with its in-house programmes ...

Avacta Annual Revenue Increases But Loss Widens On Higher Expenses

LONDON (Alliance News) - Avacta Group PLC on Tuesday said its loss widened in its recently-ended financial year on higher costs, as it continues to pr...

FIL Reduces Avacta Stake To Below 5% Threshold After Deal (ALLISS)

LONDON (Alliance News) - Avacta Group PLC said Thursday that FIL Ltd decreased its stake in the biotechnology company to below 5% after a transaction ...

Lombard Odier Asset Management Lowers Holding In Avacta (ALLISS)

LONDON (Alliance News) - Avacta Group PLC on Thursday said Lombard Odier Asset Management Europe Ltd reduced its holding in the biotechnology company....

UPDATE: Avacta Raises GBP12 Million To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC late Monday said it raised GBP11.6 million before expenses to help fund new drug develo...

Avacta Sets GBP11.4 Million Share Offer To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC on Monday said it plans to raise GBP11.4 million in a share placing and subscription to...

Avacta enters into 'groundbreaking' drug development partnership

(Sharecast News) - Avacta Group's shares surged after the biotherapeutics developer agreed a co-development partnership with Bach BioSciences, a compa...